Monetization and Contract Renewal Risk in Post-Marketing Surveillance and Marketing
First written in FY2016. 12 of 13 entries say "Restated". Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
It is stated that there have been no material changes in the risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts are disclosed in a consolidated statement as having undergone no material changes. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts are disclosed in a consolidated statement as having undergone no material changes. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risks relating to monetisation of the post-marketing research and marketing business and continuation of contracts are disclosed in a consolidated statement as having undergone no material changes. - FY2016First statedAnnual report
「Because the post-marketing surveillance business for health supplements is unprecedented, it is currently uncertain whether it will generate the expected results.」
The Group identifies contracts with physicians' organisations and academic societies, the expansion and operating costs of its medical-institution network, and the risk of failing to achieve expected revenue as risks.